Phase 1b, Open Label Study To Characterize The Distribution Of A Single Intravenous Dose Of [124i]-Iodobenzoyl (ib) Pf 06687234 With Concurrent Administration Of Non-radiolabeled Pf 06687234 As Assessed With Positron Emission Tomography And Computed Tomography (Pet-ct) Imaging In Moderate To Severe Ulcerative Colitis Subjects

Trial Profile

Phase 1b, Open Label Study To Characterize The Distribution Of A Single Intravenous Dose Of [124i]-Iodobenzoyl (ib) Pf 06687234 With Concurrent Administration Of Non-radiolabeled Pf 06687234 As Assessed With Positron Emission Tomography And Computed Tomography (Pet-ct) Imaging In Moderate To Severe Ulcerative Colitis Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs F8 IL10 (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 20 May 2019 to 29 May 2019.
    • 09 Apr 2018 Planned primary completion date changed from 20 May 2019 to 29 May 2019.
    • 09 Apr 2018 Planned initiation date changed from 28 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top